Asselah, TarikThompson, Alex JFlisiak, RobertRomero-Gomez, ManuelMessinger, DiethelmBakalos, GeorgiosShiffman, Mitchell L2023-01-252023-01-252016-03-18http://hdl.handle.net/10668/9928Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple predictive score to identify GT3 patients with a high probability of achieving a sustained virologic response (SVR) with PegIFN alfa-2a/RBV therapy. Relationships between baseline characteristics and SVR were explored by multiple logistic regression models and used to develop a simple scoring system to predict SVR using data from 1239 treatment-naive GT3 patients who received PegIFN alfa-2a/RBV for 24 weeks in two large observational cohort studies. The score was validated using a database of 473 patients. Scores were assigned for six factors as follows: age (years) (≤40: 2 points; >40 but ≤55: 1); bodyweight (kg) (40 but ≤55: 1); bodyweight (kg) (200: 2; ≥100 but A simple baseline scoring system involving age, bodyweight, cirrhosis status, ALT level, platelet count and HCV RNA level can be used to identify treatment-naive Caucasian patients with HCV GT3 infection with a high probability of SVR with PegIFN alfa-2a/RBV therapy.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AdolescentAdultAgedAntiviral AgentsFemaleGenotypeHepacivirusHepatitis C, ChronicHumansInterferon-alphaMaleMiddle AgedModels, TheoreticalPolyethylene GlycolsRecombinant ProteinsRetrospective StudiesRibavirinViral LoadYoung Adultresearch article26991780open access10.1371/journal.pone.01505691932-6203PMC4798721https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0150569&type=printablehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798721/pdf